Floatz logo

Entrectinib

Gastrointestinal Cancer

Fondazione per la Medicina PersonalizzataSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

73 Active assets in the Gastrointestinal Cancer cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Cedars-Sinai Medical Center
Phase 4BB
Irinotecan
Amgen
Phase 2BB
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 2BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Brian Anderson, MD
Phase 4BB
Epinephrine
Cedars-Sinai Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Entrectinib is also rated in:

hematopoietic and lymphoid system neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
Anatomic Stage IV Breast Cancer AJCC v8Dormant
B
Indicative ·
62 / 100
View asset →
sarcomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →